Digital Therapeutic For Schizophrenia Released Pre-Approval With FDA’s COVID-19 Digital Device Regulations During COVID-19

On April 29, 2020, Pear Therapeutics, Inc. announced it planned to launch a limited distribution program for its prescription digital therapeutic product candidate, Pear-004, for adults living with schizophrenia. Pear-004 is a product candidate in development to improve core symptoms and depression in people living with schizophrenia by providing multimodal neurobehavioral interventions in combination with standard of care anti-psychotic medication. Pear-004 provides social skills training, cognitive behavioral therapy (CBT) for psychosis, and illness self-management training. Pear-004 is designed for adults 18 years and older who are currently under the supervision of a clinical professional . . .